Table 2.

Change in BMI from baseline (visit 1) to follow-up (visit 2) in subgroups by BMI category

BMI categories	Visits	D + M		D + M + OAD		D + M and D + M + OAD
		Number of patients	BMI	Number of patients	BMI	Number of patients	BMI
≤ 24.9	Baseline visit/visit 1	12	24.02±0.54	39	23.58±1.30	51	23.68±1.18
	Follow up visit/visit 2	12	23.21±0.38	39	23.55±1.79	51	23.47±1.58
	Change in BMI	12	−0.81	39	−0.03	51	−0.21
	p-Value		0.0005		0.83		0.2838
25–29.9	Baseline visit/visit 1	30	27.26 ± 1.60	80	27.48 ± 1.36	110	27.42 ± 1.42
	Follow-up visit/visit 2	30	26.60 ± 1.76	80	27.17 ± 2.15	110	27.01 ± 2.07
	Change in BMI	30	−0.66	80	−0.31	110	−0.4
	p-Value		0.0003		0.1191		0.0082
≥30	Baseline visit/visit 1	44	35.40 ± 3.44	74	35.07 ± 15.31	118	35.20 ± 12.27
	Follow-up visit/visit 2	44	34.47 ± 3.26	74	32.51 ± 2.79	118	33.24 ± 3.11
	Change in BMI	44	−0.93	74	−2.57	118	−1.96
	p-Value		< 0.0001		0.1733		0.979

p-Values were obtained by comparing BMI at visit 2 with visit 1. p < 0.05 was consider significant by paired t test. BMI values are expressed as mean ± SD in unit kg/m²

BMI body mass index, D + M dapagliflozin + metformin, D + M + OAD dapagliflozin + metformin + other oral antidiabetic drugs